Complete Resolution of Erythrodermic Psoriasis in an HIV and HCV Patient Unresponsive to Antipsoriatic Treatments after Highly Active Antiretroviral Therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir) | Zendy

Andrea Chiricozzi | Zendy; Rosita Saraceno | Zendy; Maria Vittoria Cannizzaro | Zendy; Steven Paul Nisticò | Zendy; Sergio Chimenti | Zendy; Alessandro Giunta | Zendy

Open Access

Complete Resolution of Erythrodermic Psoriasis in an HIV and HCV Patient Unresponsive to Antipsoriatic Treatments after Highly Active Antiretroviral Therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir)

Author(s) -

Andrea Chiricozzi,

Rosita Saraceno,

Maria Vittoria Cannizzaro,

Steven Paul Nisticò,

Sergio Chimenti,

Alessandro Giunta

Publication year - 2012

Publication title -

dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.224

H-Index - 92

eISSN - 1421-9832

pISSN - 1018-8665

DOI - 10.1159/000345762

Subject(s) - medicine , atazanavir , psoriasis , emtricitabine , lopinavir , population , ritonavir , immunology , dermatology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , environmental health

Psoriasis is a chronic, inflammatory disease affecting 2-3% of the worldwide population, and it may worsen with HIV or be detected as HIV cutaneous manifestation. HIV-related psoriasis shows a severe and prolonged clinical course with more frequent exacerbations. The management of this condition is challenging because immunomodulating and immunosuppressant agents may have variable and partial efficacy, and therefore, antiretroviral treatment represents a potential adjunctive therapeutic option.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research